Royce & Associates LP Sells 82,015 Shares of Guardian Pharmacy Services, Inc. $GRDN

Royce & Associates LP trimmed its stake in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) by 30.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 186,122 shares of the company’s stock after selling 82,015 shares during the quarter. Royce & Associates LP’s holdings in Guardian Pharmacy Services were worth $5,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of GRDN. Dynamic Technology Lab Private Ltd bought a new position in Guardian Pharmacy Services during the 1st quarter worth approximately $233,000. JPMorgan Chase & Co. grew its position in Guardian Pharmacy Services by 48.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock worth $128,000 after acquiring an additional 1,956 shares during the last quarter. Legal & General Group Plc grew its position in Guardian Pharmacy Services by 1,783.1% during the 2nd quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock worth $317,000 after acquiring an additional 14,104 shares during the last quarter. Rhumbline Advisers grew its position in Guardian Pharmacy Services by 121.1% during the 2nd quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock worth $345,000 after acquiring an additional 8,860 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Guardian Pharmacy Services during the 2nd quarter worth approximately $214,000.

Guardian Pharmacy Services Stock Performance

Shares of GRDN stock opened at $39.00 on Friday. The firm has a market cap of $1.94 billion, a P/E ratio of 46.99, a P/E/G ratio of 2.54 and a beta of 0.09. Guardian Pharmacy Services, Inc. has a fifty-two week low of $19.17 and a fifty-two week high of $41.36. The business’s 50 day moving average price is $37.30 and its 200-day moving average price is $33.26.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. The firm had revenue of $336.60 million for the quarter, compared to analyst estimates of $329.89 million. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The business’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same period last year, the company earned $0.22 EPS. As a group, equities analysts predict that Guardian Pharmacy Services, Inc. will post 1.18 EPS for the current year.

Insider Transactions at Guardian Pharmacy Services

In related news, insider David K. Morris sold 187,855 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $5,575,536.40. Following the sale, the insider directly owned 254,472 shares in the company, valued at $7,552,728.96. The trade was a 42.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Fred Burke sold 671,432 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $29.68, for a total value of $19,928,101.76. Following the sale, the insider owned 840,413 shares in the company, valued at $24,943,457.84. This represents a 44.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 9,726,405 shares of company stock worth $288,679,700. Corporate insiders own 32.96% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on GRDN. Weiss Ratings lowered Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Raymond James Financial restated an “outperform” rating and set a $40.00 price target on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. UBS Group reiterated a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. Zacks Research lowered Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Jefferies Financial Group began coverage on Guardian Pharmacy Services in a research report on Monday, March 30th. They issued a “buy” rating and a $44.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.